JP5487276B2 - ヒト成長ホルモンを含有する安定した液状製剤 - Google Patents
ヒト成長ホルモンを含有する安定した液状製剤 Download PDFInfo
- Publication number
- JP5487276B2 JP5487276B2 JP2012248819A JP2012248819A JP5487276B2 JP 5487276 B2 JP5487276 B2 JP 5487276B2 JP 2012248819 A JP2012248819 A JP 2012248819A JP 2012248819 A JP2012248819 A JP 2012248819A JP 5487276 B2 JP5487276 B2 JP 5487276B2
- Authority
- JP
- Japan
- Prior art keywords
- growth hormone
- human growth
- polyethylene glycol
- liquid preparation
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title claims description 74
- 108010000521 Human Growth Hormone Proteins 0.000 title claims description 74
- 239000000854 Human Growth Hormone Substances 0.000 title claims description 74
- 239000012669 liquid formulation Substances 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 claims description 57
- 239000007788 liquid Substances 0.000 claims description 55
- -1 polyethylene Polymers 0.000 claims description 41
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 14
- 239000004698 Polyethylene Substances 0.000 claims description 14
- 229920000573 polyethylene Polymers 0.000 claims description 14
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 10
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 239000001632 sodium acetate Substances 0.000 claims description 7
- 235000017281 sodium acetate Nutrition 0.000 claims description 7
- 239000007951 isotonicity adjuster Substances 0.000 claims description 6
- 239000001509 sodium citrate Substances 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 22
- 239000003381 stabilizer Substances 0.000 description 14
- 239000004094 surface-active agent Substances 0.000 description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 11
- 239000004472 Lysine Substances 0.000 description 11
- 238000004220 aggregation Methods 0.000 description 11
- 230000002776 aggregation Effects 0.000 description 11
- 239000004359 castor oil Substances 0.000 description 11
- 235000019438 castor oil Nutrition 0.000 description 11
- 230000006240 deamidation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 11
- 229960003646 lysine Drugs 0.000 description 11
- 235000019766 L-Lysine Nutrition 0.000 description 10
- 229930064664 L-arginine Natural products 0.000 description 10
- 235000014852 L-arginine Nutrition 0.000 description 10
- 229920002564 Polyethylene Glycol 3500 Polymers 0.000 description 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002736 nonionic surfactant Substances 0.000 description 5
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 239000006076 specific stabilizer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 229940044519 poloxamer 188 Drugs 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229940044476 poloxamer 407 Drugs 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920003078 Povidone K 12 Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002410 histidine derivatives Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940124280 l-arginine Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940063149 nutropin Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
本発明の液状製剤は、凍結乾燥前の粗溶液(Bulk Solution)形態の天然型ヒト成長ホルモン(韓国のデウン社製)4.0mg/ml溶液を、pHを6.0〜6.2の範囲に調節するため、緩衝剤として、酢酸ナトリウム(シグマ社製)/クエン酸ナトリウム(シグマ社製)/燐酸二水素ナトリウム(シグマ社製)10mM水溶液と混合した〜。そして、濃度を調節した後、賦形剤(D−マンニトール(シグマ社製))、界面活性剤{マクロゴール−15ポリオキシステアリン酸塩(Solutol HS 15、BASF社製)/ポロキサマー188(Lutrol F 68、BASF社製)/ポロキサマー407(Lutrol F 127、BASF社製)/クレモフォアELP(BASF社製)/ツイーン20(CRILLET 1 HP、クロダ社製)/ツイーン80(CRILLET 4 HP、クロダ社製)}、安定化剤{ポリエチレングリコール300(PEG 300、BASF社製)/ポリエチレングリコール400(PEG 400、BASF社製)/PVP K−12(Kollidon 12 PF、BASF社製)/PVP K−15(Kollidon 15 PF、BASF社製)/L−リジン(L−Lysine・HCl、シグマ社製)/L−アルギニン(L−Arginine・HCl、シグマ社製)}、保存剤としてベンジルアルコール(韓国のデジョン社製)を混合して調剤した。
薬事上使用可能な界面活性剤がヒト成長ホルモンの安定性に及ぼす影響を調べるために、表1に記載された物質を構成成分として、実施例1と同じ方法でヒト成長ホルモンの液状製剤を調製・分析を行った。
安定化剤によるヒト成長ホルモンの液状製剤の安定化の効果を調べるために、表3に記載された物質を構成成分として、実施例1と同じ方法でヒト成長ホルモンの液状製剤を調製・分析を行った。
実施例3によってヒト成長ホルモンの液状製剤の安定化に寄与すると確認されたポリエチレングリコール300(PEG 300)リジンを使用して、液状製剤の多様な緩衝剤による安定性への影響を調べた。
本発明の液状製剤の安定性を比較実験するために、表7に記載された物質を構成成分として対照群1及び対照群2の液状製剤を調製し、実施例1のヒト成長ホルモンの液状製剤と比較検討した。
Claims (4)
- ヒト成長ホルモン;ポリエチレングリコール300;及びポリエチレングリコール−15ポリオキシステアリン酸塩を含む、液状製剤。
- ヒト成長ホルモンの量は、2.5〜5.5mg/mlであり、
ポリエチレングリコール300の量は、ヒト成長ホルモン1mg当たり、0.2〜1.0v/v%であり、
ポリエチレングリコール−15ポリオキシステアリン酸塩の量は、0.1〜0.5w/v%である、請求項1に記載の液状製剤。 - 緩衝剤、等張化剤、保存剤及び鎮痛剤から選択される一つ以上をさらに含む請求項1または2に記載の液状製剤。
- クエン酸ナトリウムまたは酢酸ナトリウムと、D−マンニトールと、ベンジルアルコールと、をさらに含み、
クエン酸ナトリウムまたは酢酸ナトリウムの量は、5〜20mMであり、
D−マンニトールの量は、20〜50mg/mlであり、
ベンジルアルコールの量は、1〜9mg/mlである、請求項1〜3のいずれか1項に記載の液状製剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012248819A JP5487276B2 (ja) | 2012-11-12 | 2012-11-12 | ヒト成長ホルモンを含有する安定した液状製剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012248819A JP5487276B2 (ja) | 2012-11-12 | 2012-11-12 | ヒト成長ホルモンを含有する安定した液状製剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009517937A Division JP5180202B2 (ja) | 2006-07-06 | 2006-07-06 | ヒト成長ホルモンを含有する安定した液状製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013056917A JP2013056917A (ja) | 2013-03-28 |
JP5487276B2 true JP5487276B2 (ja) | 2014-05-07 |
Family
ID=48133088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012248819A Active JP5487276B2 (ja) | 2012-11-12 | 2012-11-12 | ヒト成長ホルモンを含有する安定した液状製剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5487276B2 (ja) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3782737T3 (de) * | 1987-08-21 | 1999-05-20 | Imcera Group Inc | Stabilisierung von Wachstumshormonen. |
ATE359824T1 (de) * | 1992-07-31 | 2007-05-15 | Genentech Inc | Wässrige formulierung enthaltend menschliches wachstumshormon |
KR20030023878A (ko) * | 2000-06-26 | 2003-03-20 | 몬산토 테크놀로지 엘엘씨 | 소마토트로핀의 지속적인 방출을 위한 계면활성제 함유비수성 제제들 |
JP4845741B2 (ja) * | 2003-12-23 | 2011-12-28 | ファルマシア コーポレーション | 安定な成長ホルモン液体製剤 |
-
2012
- 2012-11-12 JP JP2012248819A patent/JP5487276B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2013056917A (ja) | 2013-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101953494B1 (ko) | 동결건조된 재조합 vwf 제제 | |
TW200940084A (en) | Recombinant VWF formulations | |
JP6143827B2 (ja) | hGHとrhIGF−1の組合せのための配合物 | |
JP5180202B2 (ja) | ヒト成長ホルモンを含有する安定した液状製剤 | |
KR100589878B1 (ko) | 사람 성장 호르몬을 함유한 수성 의약 조성물 | |
KR20110086583A (ko) | 제8 인자 제형 | |
KR20000010630A (ko) | 성장 호르몬, 아미노산, 및 비-이온성 세제를 함유하는 약제학적 조제무류 | |
US20240075095A1 (en) | Daptomycin formulations | |
US8178489B2 (en) | Formulation for aviptadil | |
RU2012130606A (ru) | Фармацевтические композиции, содержащие белки igf-i, буферное вещество и вещество, регулирующее тоничность | |
US20220183979A1 (en) | High concentration formulations of anti-csf1 and anti-csf1r antibodies | |
JP2016534061A (ja) | ゴナドトロピンのための新規製剤 | |
JP5487276B2 (ja) | ヒト成長ホルモンを含有する安定した液状製剤 | |
KR100769709B1 (ko) | 인성장호르몬을 함유하는 안정한 액상 제제 | |
US20030162711A1 (en) | Pharmaceutical formulation | |
US20220265782A1 (en) | Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances | |
CN105412910A (zh) | 稳定的人生长激素液体制剂 | |
WO2022034545A1 (en) | Etelcalcetide formulations for parenteral use | |
KR20120139299A (ko) | 표피세포성장인자를 함유하는 안정한 주사제용 동결건조 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140224 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5487276 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |